BioSpace News Archive

Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted two new employees a non-qualified stock option to purchase an aggregate of 14,500 shares of Calithera’s common stock, at a per share exercise price of $5.28, the closing trading price on June 30, 2020.

Study design presented at the ESMO World Congress on Gastrointestinal Cancer2020

The iRemedy Healthcare Companies, Inc., pioneer of the iRemedy ecommerce platform, announced its intent to spearhead the formation of the American Medical Manufacturing Coalition, bringing together U.S.-based manufacturers, distributors, investors, healthcare providers and government to rapidly advance the establishment of a strong and pervasive healthcare manufacturing base in America.

Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file its quarterly report on Form 10-Q for the third quarter of its 2020 fiscal year, the period ended May 31, 2020, on Thursday, July 9, 2020.

FDA’s “Enforcement Policy” and Orexo’s strong financial position enable investments in an accelerated commercialization of its scientifically proven digital therapies

The CDC “considers a person to have a fever when he or she has a measured temperature of 100.4° F (38° C) or greater.”

Canalevia would be first and only FDA-approved plant-based medicine for working dogs that suffer from diarrhea

According to Coherent Market Insights, the global digital microscopes market is estimated to be valued at US$ 1,124.0 million in 2020, and is expected to exhibit a CAGR of 6.5% during the forecast period (2020-2027).

Strategic Vaccines, LLC has signed a Memorandum of Understanding with the Texas A&M Center for Innovation in Advanced Development and Manufacturing to establish a FlowVax vaccine platform manufacturing center at Texas A&M’s College Station to rapidly respond to emerging viral threats.

Intellipharmaceutics International Inc. (OTCQB:IPCIF) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that the parties in the cases, numbers 17-cv-392-RGA, 18-cv-404-RGA and 20-cv-515-RGA (the “Litigations”) between Purdue Pharma L.P. e